Document is current
Any future updates will be listed below
-
Authors
Woo, Hawon https://orcid.org/0009-0006-7507-4217
Jang, Yeonseo
Kim, Soyeon https://orcid.org/0009-0001-9046-6175
Kim, Wonyoung
Zhang, Fenfen
Mall, Raghvendra https://orcid.org/0000-0003-1779-3150
Patel, Chirag N https://orcid.org/0000-0003-0777-7720
Kurera, Melan
Ngo, Chinh
Jiang, Simon H
Nicotra, Asia
Py, Bénédicte F https://orcid.org/0000-0001-6716-7807
Zheng, Min https://orcid.org/0009-0003-9811-4937
Man, Si Ming https://orcid.org/0000-0002-5079-2857
Karki, Rajendra https://orcid.org/0000-0003-4436-9128
-
Funding
Funding for this research was provided by:
MOST | National Key Research and Development Program of China (2024YFA0920003)
National Research Foundation of Korea (RS-2023-00251395)
National Research Foundation of Korea (RS-2025-00554099)
National Research Foundation of Korea (RS-2024-00440738)
CSL Limited (CSL Centenary Fellowship)
Seoul National University (Creative-Pioneering Researchers Program, 3344-20240032)
- License Information
-
More Information
Article History
Received: 6 November 2025
Revised: 20 March 2026
Accepted: 25 March 2026
First Online: 17 April 2026
Disclosure and competing interests statement
: HW, YJ, and RK reported patent applications related to LOC14 and isothiazolinone compounds as inhibitors of the NLRP3 inflammasome. A Korean patent application (KR 10-2025-0120917) has been filed by Seoul National University, with these authors listed as inventors. An international PCT application (PCT/KR2025/021991) claiming priority from this Korean application has also been filed. The remaining authors declare no competing interests.
